Program Description
Myelodysplastic syndromes (MDS) refers to a heterogeneous group of hematologic malignancies characterized by abnormal bone marrow, blood cell morphology, and peripheral blood cytopenias resulting in abnormal blood development. Treatment of high-risk MDS is currently limited compared with other hematologic malignancies, with patients experiencing increased likelihood of relapse or progression to acute myeloid leukemia. Evidence-based recommendations for treatment sequencing exist, but patient-specific factors, including age, comorbidities, renal function, depth of cytopenias, and presence of cytogenetic abnormalities, can influence treatment selection. In addition to treatment challenges, pharmacists must understand barriers influencing patient access, financial considerations, and health care resource utilization in the treatment and management of high-risk MDS. This webinar will review clinical data for emerging agents incorporating molecularly targeted approaches with a focus of evidence presented at the 2022 American Society of Hematology Annual Meeting. The potential impact of recently presented data on current clinical practice guidelines will be reviewed to assist managed care professionals in navigating cost-effective treatment for patients with high-risk MDS.
Target audience: Managed care and oncology pharmacists
Type of activity: Application
Release date: December 15, 2022
Expiration date: February 15, 2023
Time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the current treatment landscape of high-risk myelodysplastic syndromes (HR MDS) and updates in the International Prognostic Scoring System risk stratification
- Analyze recent clinical updates on novel and emerging pharmacotherapeutic approaches in the treatment of HR MDS presented at the 2022 American Society of Hematology Annual Meeting
- Apply the managed care considerations to appropriately assess and integrate new data to improve the care for patients with HR MDS
Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager, Adult Leukemia/Lymphoma
Program Director, PGY2 Oncology Pharmacy Residency
New York-Presbyterian Hospital, Columbia University Irving Medical Center
New York, New York
Sara Moran Smith, PharmD, BCOP
Oncology Pharmacy Program Manager
Allina Health
Minneapolis, Minnesota
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-579-L01-P. The activity is available for CE credit through February 15, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Peter Campbell, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant: Pharmacosmos
Sara Moran Smith, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: Karyopharm; Consultant: G1 Therapeutics
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms